Submit Data |  Help |  Video Tutorials |  News |  Publications |  FTP Download |  REST API |  Citing RGD |  Contact   

Evaluation of a previously suggested plasma biomarker panel to identify Alzheimer's disease.

Authors: Bjorkqvist, M  Ohlsson, M  Minthon, L  Hansson, O 
Citation: Bjorkqvist M, etal., PLoS One. 2012;7(1):e29868. doi: 10.1371/journal.pone.0029868. Epub 2012 Jan 18.
Pubmed: (View Article at PubMed) PMID:22279551
DOI: Full-text: DOI:10.1371/journal.pone.0029868

There is an urgent need for biomarkers in plasma to identify Alzheimer's disease (AD). It has previously been shown that a signature of 18 plasma proteins can identify AD during pre-dementia and dementia stages (Ray et al, Nature Medicine, 2007). We quantified the same 18 proteins in plasma from 174 controls, 142 patients with AD, and 88 patients with other dementias. Only three of these proteins (EGF, PDGF-BB and MIP-1delta) differed significantly in plasma between controls and AD. The 18 proteins could classify patients with AD from controls with low diagnostic precision (area under the ROC curve was 63%). Moreover, they could not distinguish AD from other dementias. In conclusion, independent validation of results is important in explorative biomarker studies.


Disease Annotations
Objects Annotated

Additional Information

CRRD Object Information
CRRD ID: 10449445
Created: 2016-01-05
Species: All species
Last Modified: 2016-01-05
Status: ACTIVE


RGD is funded by grant HL64541 from the National Heart, Lung, and Blood Institute on behalf of the NIH.